← Human Trials & Peer-Reviewed Studies
Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.
Plain-language guide to PMID 28065190 (2016): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).
Key Facts
- PMID
- 28065190
- Journal
- The British journal of nutrition
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Wetmore JB et al. (4 authors)
- DOI
- 10.1017/S000711451600427X
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).
The primary outcome was change in total 25(OH)D from baseline to week 12 (immediately after therapy).
Secondary analyses included the change in 1,25-dihydroxyvitamin D (1,25(OH)2D), parathyroid hormone (PTH), D2 and D3 sub-fractions of 25(OH)D and 1,25(OH)2D and total 25(OH)D from baseline to week 18 (6 weeks after therapy).
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized and double-blind study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
What Was Measured
The primary outcome was change in total 25(OH)D from baseline to week 12 (immediately after therapy).
Secondary analyses included the change in 1,25-dihydroxyvitamin D (1,25(OH)2D), parathyroid hormone (PTH), D2 and D3 sub-fractions of 25(OH)D and 1,25(OH)2D and total 25(OH)D from baseline to week 18 (6 weeks after therapy).
PubMed files the paper under topics including 25-Hydroxyvitamin D 2, Academic Medical Centers, Calcifediol, Calcitriol, Cholecalciferol, Cohort Studies and Dietary Supplements.
The authors tagged it with the keywords 1, 25(OH)D 25-hydroxyvitamin D, CKD chronic kidney disease, 25(OH)2D 1, 25-dihydroxyvitamin D and Chronic kidney disease.
What This Means in Plain Language
The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).
The publication is from 2016 (The British journal of nutrition), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compounds
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.